Compare AbbVie Inc (ABBV) vs iShares MSCI South Korea ETF (EWY) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

EWY (iShares MSCI South Korea ETF) trades at $166.09, up 1.2% with a neutral technical signal. The ETF faces volatility from South Korea's AI and semiconductor exposure, with recent news highlighting both government support initiatives and significant market swings. Technical indicators show mixed signals with RSI at 75.01 suggesting overbought conditions while moving averages remain bullish.

The outlook remains cautious as South Korean equities navigate AI-driven volatility and regulatory changes. Goldman Sachs maintains strong conviction with 90% upside potential for Korean stocks, but recent ETF speculation curbs and semiconductor stock declines present near-term headwinds for EWY investors.